

ASX RELEASE

21 June 2023

AMP945 International Nonproprietary Name “Narmafotinib” Announced

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the International Nonproprietary Name (INN) for AMP945 is narmafotinib.

The process for naming a drug compound requires an extensive process of review prior to approval. These reviews take into account similarity with other drug names, ease of pronunciation across multiple languages, language review for accidental meaning, and finally a period for parties to report an objection to the name. With these processes now complete the Company is now free to use the name narmafotinib for AMP945.

Amplia’s CEO and Managing Director, Dr Chris Burns, commented:

“Approval of the name narmafotinib is an important step in the commercial development of the drug, signalling to potential partners and collaborators our commitment to the long-term development of this exciting agent.”

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/amplia-therapeutics).